Quantum BioPharma Ltd. (NASDAQ: QNTM) has been featured in a BioMedWire editorial that examines the potential of its lead candidate, Lucid-MS, to overcome the limitations of current multiple sclerosis (MS) treatments. The editorial highlights the U.S. Food and Drug Administration's clearance for Quantum to launch a Phase 2 trial of Lucid-MS, a patented, first-in-class drug designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, this trial would mark the first time a drug based on this mechanism is tested in people living with MS.
The significance of this development lies in its departure from existing MS therapies. Most approved treatments for MS work by modulating or suppressing the immune system to reduce relapses and slow disability progression. However, they do not directly repair the damage to myelin, the protective coating around nerve fibers that is destroyed in MS. Lucid-MS, developed by Quantum's wholly owned subsidiary Lucid Psycheceuticals Inc., is a new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. If successful in clinical trials, it could represent a paradigm shift in MS treatment by addressing the disease's root cause rather than just its symptoms.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's focus on myelin repair is part of a broader effort to develop therapies that can restore function in patients with demyelinating diseases. For investors, the FDA clearance of the Phase 2 trial is a critical milestone that validates the company's scientific approach and brings it one step closer to potentially commercializing a novel therapy. The MS market is substantial, with a high unmet need for treatments that can reverse disability, and a successful myelin-repair drug could capture significant share.
In addition to its MS program, Quantum has invented UNBUZZD(TM), an over-the-counter product spun out to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. This diversified asset base provides additional potential revenue streams and underscores the company's commitment to addressing a range of health challenges.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/whtAF.
For more information about InvestorWire, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
